User login
Key clinical point: Switching to intravenous eptinezumab may benefit patients with treatment-refractory migraine who have previously failed subcutaneous calcitonin gene-related peptide-receptor (CGRP-R) monoclonal antibodies (mAbs).
Major findings: At 12 and 24 weeks of eptinezumab treatment, 23.1% and 29.7% of patients had ≥30% reduction in monthly migraine days, whereas 15.4% and 21.4% had ≥30% reduction in monthly headache days, respectively. At 21-24 weeks, 38.5% and 52.4% of patients showed significant reductions in the Headache Impact Test and Migraine Disability Assessment scores, respectively. No adverse events were reported during the 24-week treatment period.
Study details: This monocentric retrospective longitudinal cohort study included 41 patients with migraine unresponsive to ≥1 subcutaneous CGRP mAb, who received an initial 100 mg dose of intravenous eptinezumab, followed by 100 or 300 mg after 12 weeks.
Disclosure: This study was supported by the Lundbeck Foundation. Several authors declared receiving personal fees from various sources.
Source: Triller P, Blessing VN, Overeem LH, et al. Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study. Cephalalgia. Published online October 29, 2024. Source
Key clinical point: Switching to intravenous eptinezumab may benefit patients with treatment-refractory migraine who have previously failed subcutaneous calcitonin gene-related peptide-receptor (CGRP-R) monoclonal antibodies (mAbs).
Major findings: At 12 and 24 weeks of eptinezumab treatment, 23.1% and 29.7% of patients had ≥30% reduction in monthly migraine days, whereas 15.4% and 21.4% had ≥30% reduction in monthly headache days, respectively. At 21-24 weeks, 38.5% and 52.4% of patients showed significant reductions in the Headache Impact Test and Migraine Disability Assessment scores, respectively. No adverse events were reported during the 24-week treatment period.
Study details: This monocentric retrospective longitudinal cohort study included 41 patients with migraine unresponsive to ≥1 subcutaneous CGRP mAb, who received an initial 100 mg dose of intravenous eptinezumab, followed by 100 or 300 mg after 12 weeks.
Disclosure: This study was supported by the Lundbeck Foundation. Several authors declared receiving personal fees from various sources.
Source: Triller P, Blessing VN, Overeem LH, et al. Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study. Cephalalgia. Published online October 29, 2024. Source
Key clinical point: Switching to intravenous eptinezumab may benefit patients with treatment-refractory migraine who have previously failed subcutaneous calcitonin gene-related peptide-receptor (CGRP-R) monoclonal antibodies (mAbs).
Major findings: At 12 and 24 weeks of eptinezumab treatment, 23.1% and 29.7% of patients had ≥30% reduction in monthly migraine days, whereas 15.4% and 21.4% had ≥30% reduction in monthly headache days, respectively. At 21-24 weeks, 38.5% and 52.4% of patients showed significant reductions in the Headache Impact Test and Migraine Disability Assessment scores, respectively. No adverse events were reported during the 24-week treatment period.
Study details: This monocentric retrospective longitudinal cohort study included 41 patients with migraine unresponsive to ≥1 subcutaneous CGRP mAb, who received an initial 100 mg dose of intravenous eptinezumab, followed by 100 or 300 mg after 12 weeks.
Disclosure: This study was supported by the Lundbeck Foundation. Several authors declared receiving personal fees from various sources.
Source: Triller P, Blessing VN, Overeem LH, et al. Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study. Cephalalgia. Published online October 29, 2024. Source